Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
OtherClinical Investigations (Human)

177Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer

Jie Zang, Qingxing Liu, Huimin Sui, Rongxi Wang, Orit Jacobson, Xinrong Fan, Zhaohui Zhu and Xiaoyuan Chen
Journal of Nuclear Medicine May 2020, jnumed.120.242263; DOI: https://doi.org/10.2967/jnumed.120.242263
Jie Zang
1 Peking Union Medical College Hospital, China;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qingxing Liu
2 Peking Union Medical University Hospital, China;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Huimin Sui
1 Peking Union Medical College Hospital, China;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rongxi Wang
1 Peking Union Medical College Hospital, China;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Orit Jacobson
3 National Institutes of Health, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xinrong Fan
1 Peking Union Medical College Hospital, China;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhaohui Zhu
1 Peking Union Medical College Hospital, China;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoyuan Chen
3 National Institutes of Health, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Xiaoyuan Chen
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Additional Files

  • Supplemental Data

    Files in this Data Supplement:

    • Supplemental Data
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 66 (5)
Journal of Nuclear Medicine
Vol. 66, Issue 5
May 1, 2025
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
177Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
177Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer
Jie Zang, Qingxing Liu, Huimin Sui, Rongxi Wang, Orit Jacobson, Xinrong Fan, Zhaohui Zhu, Xiaoyuan Chen
Journal of Nuclear Medicine May 2020, jnumed.120.242263; DOI: 10.2967/jnumed.120.242263

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
177Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer
Jie Zang, Qingxing Liu, Huimin Sui, Rongxi Wang, Orit Jacobson, Xinrong Fan, Zhaohui Zhu, Xiaoyuan Chen
Journal of Nuclear Medicine May 2020, jnumed.120.242263; DOI: 10.2967/jnumed.120.242263
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Dansylated Amino Acid-Modified Long-Acting PSMA Derivatives 68Ga/177Lu-LNC1011 as Prostate Cancer Theranostics
  • A Single-Arm, Low-Dose, Prospective Study of 177Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
  • Google Scholar

More in this TOC Section

Clinical Investigations (Human)

  • The added value of 18F-FDG PET/CT compared to 68Ga-PSMA PET/CT in patients with castration-resistant prostate cancer
Show more Clinical Investigations (Human)

Clinical (Radionuclide Therapy)

  • Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice
Show more Clinical (Radionuclide Therapy)

Similar Articles

Keywords

  • radionuclide therapy
  • 177Lu
  • Evans blue
  • metastatic castration-resistant prostate cancer (mCRPC)
  • prostate-specific membrane antigen (PSMA)
  • radioligand therapy (RLT)
SNMMI

© 2025 SNMMI

Powered by HighWire